Business Wire

IQM's Q-Exa Consortium Selected to Integrate German Quantum Computer Into HPC Supercomputer for the First Time

15.11.2021 20:44:00 EET | Business Wire | Press release

Share

IQM Quantum Computers has been selected to provide a quantum computing system that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. The delivery is part of a €45.3 million consortium project. The project is funded by the German Federal Ministry of Education and Research (BMBF) with €40.1 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115006110/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Picture: Federal Minister Anja Karliczek hands over the grant certificate to Jan Goetz, CEO of IQM Picture credit: BMBF/Hans-Joachim Rickel

The highly interdisciplinary consortium with experts from quantum physics and computer science, from research centers and industry, will integrate a quantum computing system provided by IQM into an HPC environment via a research purchase. This will be the first time that a gate-based quantum system will be coupled with an HPC system, making quantum acceleration of HPC applications a reality.

Quantum computers have significant potential for solving a certain class of scientific and industrial problems that cannot be addressed by classical supercomputers. To meet this challenge, HPC centers around the world are looking for ways to integrate quantum accelerators into their computing infrastructure. The ability to provide on-site solutions for quantum computing in conjunction with supercomputers is essential for the development of cutting-edge high-tech solutions from Europe. The main goal of the Q-Exa project is to establish such solutions and thus strengthen the application- related use of quantum technologies from Germany.

IQM will work with Leibniz Supercomputing Centre, LRZ - one of Germany's three national supercomputing centers, Europe's leading HPC and quantum system provider (Atos) and one of Germany's leading innovators of quantum computing applications (HQS) on this project.

Q-Exa's collaborative approach creates strong synergies with other research projects in the German and European ecosystem. The previously announced BMBF project DAQC benefits from novel simulators and fits seamlessly into the concept of the Q-Exa Co-Design Lab. The new Co-Design lab will accelerate the path to self-sustaining quantum computing, the so-called quantum advantage, through industry partnerships. This approach is in line with other German industry efforts, such as the recently formed QUTAC consortium. On the application side, research consortia such as the BMBF projects QLindA, MANIQU and other initiatives support development as industrial use cases can be tested on the Q-Exa demonstrators. Finally, the Q-Exa project supports the European strategy based on integrating quantum computing accelerators into European HPC centers. With Q-Exa, Germany can make an active contribution to these European efforts.

Federal Research Minister Anja Karliczek says: "The international race in the field of quantum technologies is in full swing. Germany and the European Union must do their utmost to keep pace in order to guarantee our technological sovereignty. We want to be able to autonomously use the technology and develop it further. The Q-Exa project opens a new promising chapter on our path to a quantum computer 'made in Germany'. Integrating a quantum computer with the infrastructure of the Leibniz Supercomputing Centre harbours enormous potential for science and industry. The project will contribute to bringing quantum computers close to practice and to provide specific application scenarios for users in science and industry. I am delighted that by launching the project we have reached the first milestone on the way towards a competitive quantum computer 'made in Germany'."

Dr. Jan Goetz, CEO of IQM Quantum Computers remarks: "We are pleased to deliver a quantum computing system to LRZ and to work with the consortium partners to integrate this system into a production-grade HPC environment. I am grateful to the Federal Ministry of Education and Research in Germany, which has given us the necessary trust and support for this ambitious project. Together we will work hard to make European technology competitive and develop the most promising hardware solutions for quantum computing here in Germany".

Prof. Dr. Dieter Kranzlmuller, Chairman of the Board of Directors, LRZ, points out: “The Q-Exa project is key for our activities within the LRZ Quantum Integration Centre (QIC) and the Munich Quantum Valley (MQV). Working with this extremely competitive consortium, we will be able to set European standards that are competitive on a global scale. Ultimately, this will be for the benefit of society as the integration of quantum computing into supercomputers, in particular on the exascale level, will speed up and open vast new research possibilities. It will bring quantum computing to users – both in academia and in industry. And now is exactly the right time to realize this in a data center environment”.

“Technological sovereignty in strategic areas like quantum computing is critical for Europe. With our Quantum Learning Machine (QLM) and strong startup partners like IQM, Atos is proud to contribute to this joint effort. It is time to build the first German quantum computer, connected to an HPC datacenter through our QLM”, says Udo Littke, Head of Atos Central Europe.

„Quantum computers will accelerate scientific progress and the development of new technologies in many areas. Chemistry, physics and biology can potentially profit from the ability to perform improved quantum mechanical simulations. Therefore, it is the next logical step to integrate quantum computers into high performance computer centers like the LRZ. We are looking very much forward to connect the end users of the LRZ with the necessary software tools to make full use of the coming computational capabilities”, says Dr. Michael Marthaler, CEO HQS Quantum Simulations GmbH.

About IQM Quantum Computers:

IQM is the Pan-European category leader in building quantum computers.

IQM delivers on-premises quantum computers for supercomputing centers and research laboratories and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium was awarded a project to develop application-specific quantum processors by the German Ministry of Education and Research in February 2021.

IQM has raised €71 million from private and public funding and has offices in Munich, Germany; Espoo, Finland; and Bilbao, Spain.

For more information, visit www.meetiqm.com.

IQM: Facts and Figures

  • Number of employees currently (November 2021): 130+ employees
  • Funding: Over € 71 Million from private and public funding
  • Founding Year: 2018

Founders:

  • Dr. Jan Goetz, CEO, Co-founder of IQM
  • Dr. Kuan Yen Tan, CTO, Co-founder of IQM
  • Prof. Mikko Mottonen, Chief scientist, Co-founder of IQM
  • Dr. Juha Vartiainen, COO, Co-founder of IQM

For more information, visit www.meetiqm.com.

Registered offices:

IQM Finland Oy Keilaranta 19
02150 Espoo Finland

IQM Germany GmbH Nymphenburgerstr. 86 80636 Munchen Germany

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Raghunath Koduvayur, Head of Marketing and Communications
Raghunath@meetiqm.com, +358504876509

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye